Bluebird Bio Withdrawal Raises Gene Therapy Doubts in Europe
Last month, the US firm bluebird bio abandoned the sale of its gene therapy Zynteglo…
04/05/2021 - 5 minutes
Anita Chakraverty
Anita Chakraverty is a freelance medical journalist and science communicator. Outside work, she enjoys a good movie, long walks in the local woods, and trying to get into pretzel-like yoga poses.
Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions
The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in…
20/04/2021 - 5 minutes
Artios-Novartis Pact Pushes Limits of DNA Repair in Cancer
A €1.1B deal struck this week between Novartis and the UK-based company Artios Pharma forges…
08/04/2021 - 5 minutes
Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells
The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with…
31/03/2021 - 5 minutes
Europe Falls Behind in Efforts to Track Covid-19 Variants
As barely a third of European countries meet targets to track concerning Covid-19 variants, diagnostics…
18/03/2021 - 5 minutes
Legal Fights Accompany Big Fundraises in Liquid Biopsy Scene
A recent patent fight between the liquid biopsy companies Natera and Inivata is only the…
25/02/2021 - 5 minutes
Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze
The major research funder CRUK and two of the biotech companies it works with have…
16/02/2021 - 4 minutes
HIV Drug Approvals Lift Hopes Amid Missed UN Targets
The recent approvals of long-acting HIV injections promise to lighten the load of HIV sufferers…
04/02/2021 - 6 minutes
Kymab Wins UK Supreme Court Antibody Battle Against Regeneron
The UK Supreme Court has supported an appeal by British biotech Kymab to revoke antibody…
30/06/2020 - 4 minutes
Update: Fifth US Antibody Patent Owned by UK Biotech Upheld in Regeneron Battle
Update (04/06/2020): After upholding four of Kymab's patents addressing the production of antibody drugs earlier…
04/06/2020 - 4 minutes
Phase II Fail Ends Swiss-US Drug for Rare Kidney Disease
An initially promising drug has failed to show benefits in a phase II trial for…
22/05/2020 - 2 minutes
Oncopeptides’ Share Issue Bags €133M to Take Cancer Drug to Market
Swedish biotech Oncopeptides has raised €133M (SEK 1.4B) by issuing new company shares, surpassing expectations…
14/05/2020 - 3 minutes
